[18F]FDG PET/MRI in rectal cancer

AbstractWe conducted a systematic literature review on the use of [18F]FDG PET/MRI for staging/restaging rectal cancer patients with PubMed, Scopus, and Web of Science, based on the PRISMA criteria. Three authors screened all titles and abstracts and examined the full texts of all the identified  relevant articles. Studies containing aggregated or duplicated data, review articles, case reports, editorials, and letters were excluded. Ten reports met the inclusion criteria. Four studies examined T staging and one focused on local recurrences after surgery; the reported sensitivity (94–100% ), specificity (73–94%), and accuracy (92–100%) varied only slightly from one study to another. The sensitivity, specificity, and accuracy of [18F]FDG PET/MRI forN staging were 90 –93%, 92–94%, and 42–92%. [18F]FDG PET/MRI detected malignant nodes better than MRI, resulting in treatment change. ForM staging, [18F]FDG PET/MRI outperformed [18F]FDG PET/CT and CT in detecting liver metastases, whereas it performed worse for lung metastases. The results of this review suggest that [18F]FDG PET/MRI should be used for rectal cancer restaging after chemoradiotherapy and to select patients for rectum-sparing approaches thanks to its accuracy inT andN staging. ForM staging, it should be associated at least with a chest CT scan to rule out lung metastases.
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research